Evidence map›Paper›PMID 37604489›Full record

ArticleESC heart failure2023

Utility of left ventricular ejection fraction in atrial fibrillation patients without pre-existing heart failure.

Yasuhiro Hamatani, Moritake Iguchi, Kimihito Minami, Kenjiro Ishigami, Masahiro Esato, Hikari Tsuji, Hiromichi Wada, Koji Hasegawa, Hisashi Ogawa, Mitsuru Abe and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. 2024 update in heart failure.ESC heart failure · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Yasuhiro HamataniDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Moritake IguchiDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Kimihito MinamiDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Kenjiro IshigamiDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Masahiro EsatoDepartment of Arrhythmia, Ogaki Tokushukai Hospital, Gifu, Japan.
Hikari TsujiTsuji Clinic, Kyoto, Japan.
Hiromichi WadaDivision of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Koji HasegawaDivision of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Hisashi OgawaDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Mitsuru AbeDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Gregory Y H LipLiverpool Center for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK.
Masaharu AkaoDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.ORCID 0000-0002-2348-7646
Fushimi AF Registry investigators
Kyoto Medical Center · JPFukuoka Tokushukai Hospital · JPUji Hospital · JPUniversity of Liverpool · GB

Funding

Astellas PharmaAstraZenecaBayer HealthcareBoehringer IngelheimBristol-Myers SquibbDaiichi Sankyo CompanyJapan Agency for Medical Research and Development 18ek0210056h0003Japan Agency for Medical Research and Development 19ek0210082h0003MSDNovartis PharmaPfizerSanofi-AventisTakeda Pharmaceutical Company
6 · The paper itself

Abstract

aimsAtrial fibrillation (AF) increases the risk of heart failure (HF); however, little focus has been placed on the prevention of HF in patients with AF. Left ventricular ejection fraction (LVEF) is an established echocardiographic parameter in HF patients. We sought to investigate the association of LVEF with HF events in AF patients without pre-existing HF. METHODS AND

resultsThe Fushimi AF Registry is a community-based prospective survey of AF patients in Fushimi-ku, Japan. In this analysis, we excluded patients with pre-existing HF (defined as having one of the following: prior HF hospitalization, New York Heart Association class ≥ 2 in association with heart disease, or LVEF < 40%). Among 3233 AF patients without pre-existing HF, we investigated 2459 patients with the data of LVEF at enrolment. We divided the patients into three groups stratified by LVEF [mildly reduced LVEF (40-49%), below normal LVEF (50-59%), and normal LVEF (≥60%)] and compared the backgrounds and incidence of HF hospitalization between the groups. Of 2459 patients [mean age: 72.4 ± 10.5 years, female: 917 (37%), paroxysmal AF: 1405 (57%), and mean CHA

conclusionsLower LVEF was significantly associated with the higher incidence of HF hospitalization in AF patients without pre-existing HF, leading to the future risk stratification for and prevention of incident HF in AF patients.

Indexed as

Atrial FibrillationHeart FailureRegistriesStroke VolumeVentricular Function, LeftAgedEchocardiographyFemaleFollow-Up StudiesHospitalizationHumansIncidenceJapanMalePrognosisProspective StudiesAtrial fibrillationHeart failureLeft ventricular ejection fraction

Identifiers

PMID37604489
PMCPMC10567650
OpenAlexW4386046490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.